VistaGen
Therapeutics, a biotechnology company applying pluripotent stem cell technology
for drug rescue and regenerative medicine, reports that it is now a member of
the Cardiac Safety Technical Committee, Cardiac Stem Cell Working Group, and
Proarrhythmia Working Group of the Health and Environmental Sciences Institute
(HESI).
Using mature
cardiomyocytes (heart cells) differentiated from human pluripotent stem cells,
VistaGen developed its CardioSafe 3D™ bioassay system to predict the in vivo
cardiac effects, both toxic and non-toxic, of small molecule drug candidates
with greater speed and precision than the traditional, surrogate safety models
most often used in drug development. The company’s pluripotent stem
cell-derived heart cells and CardioSafe 3D are vital components of its Human
Clinical Trials in a Test Tube™ platform and drug rescue programs.
Ralph Snodgrass,
Ph.D., VistaGen’s president and chief scientific officer commented, “We look
forward to collaborating with leading pharmaceutical, biotechnology, academic,
and regulatory members of the HESI’s Cardiac Safety Technical Committee, and
related working groups, to help advance, among other goals, the FDA’s CIPA
initiative, which is focused on developing innovative preclinical systems for
cardiac safety assessment during drug development.”
HESI, a global
branch of the International Life Sciences Institute (ILSI), boasts a membership
roll that includes most of the world’s largest biotechnology and pharmaceutical
companies for which it provides an international forum to advance the
understanding of scientific issues related to human health, toxicology, risk
assessment, and the environment. ILSI is a nonprofit, worldwide organization
whose mission is to provide science that improves human health and well-being
and safeguards the environment.
Operating from its
headquarters in San Francisco, California, VistaGen contends that better cells
lead to better medicine and that the key to making better cells is controlling
with precision the differentiation of human pluripotent stem cells, which are
the base cells of the human body.
For more information
on the company visit www.VistaGen.com/
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment